Edith Perez

VP, USMA BioOncology
Edith provides strategic and scientific leadership for all BioOncology Medical Affairs activities in the US. Her primary focus is to develop and implement medical strategies to optimize the appropriate utilization of our cancer medicines, resulting in the right patients receiving the right products at the right time. In collaboration with functions across USMA and Genentech, Edith and her team will lead a broad spectrum of oncology medical affairs activities including phase IV trials, medical education, publications, medical communication, advisory boards, promotional material review, and product launches. She will also actively participate and contribute to key US and global leadership teams and collaborate with a broad range of stakeholders across the company.

Edith is a renowned cancer specialist with over 20 years of experience who has gained international recognition for her work on translational research. She held numerous leadership positions at Mayo Clinic in Jacksonville, FL, including her role as Director of the Breast Cancer Translational Genomics Program. Most recently, she served as Deputy Director at Large of the Mayo Clinic Cancer Center (in Rochester, MN) and Director of the Breast Specialty Council.Edith was also a Serene M. and Frances C. Durling Professor of Medicine at the Mayo Medical School. She completed her residency in internal medicine at the Loma Linda University Medical Center in California and her fellowship in hematology and oncology at the University of California, Davis.Throughout her professional career, Edith played an instrumental role in a wide range of trials and research studies that explored the use of new therapeutic agents for the treatment and prevention of breast cancer. Edith’s connection to Genentech and our shared mission is a special one that started over a decade ago — her groundbreaking work as the principal investigator of one of the landmark trials for the adjuvant treatment of breast cancer by using Herceptin in combination with chemotherapy paved the way for the 2005 discovery that fundamentally changed how we manage treatment for HER2-positive patients. Edith’s roles extend nationally, including positions with leading institutions such as the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI). She continues to serve on the editorial boards of multiple academic journals and has authored over 700 research articles and abstracts. Edith has been recognized for her significant contributions to the oncology community through many prestigious honors, including the Susan G. Komen Brinker Award for Scientific Distinction in Clinical Research and the Mayo Clinic Distinguished Investigator Award.